Table 2.
Univariate and multivariate analyses of overall survival (OS)
| Characteristic | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Sex | ||||
| Female | 1 (reference) | 0.274 | ||
| Male | 1.529 (0.714–3.274) | |||
| HBV infection | ||||
| No | 1 (reference) | 0.306 | ||
| Yes | 1.461 (0.707–3.021) | |||
| Tumor number | ||||
| Solitary | 1 (reference) | 0.882 | ||
| Multiple | 1.068 (0.604–1.886) | |||
| TNM stage | ||||
| Early | 1 (reference) | <0.001 | 0.072 | |
| Moderate | 2.420 (0.835–7.014) | |||
| Advanced | 7.479 (2.503–22.342) | |||
| Initial treatment | ||||
| ST | 1 (reference) | <0.001 | 1 (reference) | <0.001 |
| TACE | 0.298 (0.150–0.592) | 0.298 (0.150–0.592) | ||
| Resection | 0.105 (0.048–0.226) | 0.105 (0.048–0.226) | ||
| Distant metastasis | ||||
| No | 1 (reference) | 0.018 | 0.448 | |
| Yes | 2.360 (1.156–4.815) | |||
| Portal vein tumor thrombus | ||||
| No | 1 (reference) | 0.001 | 0.184 | |
| Yes | 2.725 (1.484–5.004) | |||
| Tumor diameter (cm) | ||||
| ≤5 | 1 (reference) | 0.215 | ||
| >5 | 1.912 (0.687–5.323) | |||
| TBIL (μmol/L) | ||||
| ≤20.5 | 1 (reference) | 0.023 | 0.944 | |
| >20.5 | 1.947 (1.094–3.465) | |||
| AST (U/L) | ||||
| ≤45 | 1 (reference) | 0.006 | 0.786 | |
| >45 | 2.365 (1.287–4.346) | |||
| ALT (U/L) | ||||
| ≤40 | 1 (reference) | 0.059 | ||
| >40 | 1.702 (0.979–2.959) | |||
| ALB (g/L) | ||||
| ≤35 | 1 (reference) | 0.457 | ||
| >35 | 0.676 (0.242–1.893) | |||
| AFP (g/L) | ||||
| ≤25 | 1 (reference) | 0.606 | ||
| >25 | 1.309 (0.47–3.649) | |||
HBV hepatitis B virus, TNM tumor-node-metastasis, ST supportive treatment, TACE transcatheter arterial chemoembolization, TBIL total bilirubin, AST aspartate transaminase, ALT alanine aminotransferase, ALB albumin, AFP alpha-fetoprotein